The New England journal of medicine
-
Randomized Controlled Trial
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. ⋯ In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
-
Letter Case Reports
Late-Onset Neonatal Sepsis in a Patient with Covid-19.